|
|
Vaccine Detail
|
Nap-G(D)F(D)F(D)Y(D)K-TSAPDT(Tn)RPAP Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: Nap-G(D)F(D)F(D)Y(D)K-TSAPDT(Tn)RPAP Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Licensed
- Host Species for Licensed Use: Baboon
- Antigen: MUC1 (Liu et al., 2017)
- Immunization Route: subcutaneous injection
- Description: A self-adjuvanting peptide-based cancer vaccine consisting of the MUC1 tumor-associated glycopeptide antigen TSAPDT(?-GalNAc)RPAP covalently conjugated to the self-assembling peptide nanovector Nap-G?F?F?Y?K. The nanovector, composed of naphthylacetic acid and D-amino acids, self-assembles into nanoparticles and serves as both carrier and adjuvant, eliminating the need for external adjuvants. Vaccination elicited robust humoral and cellular immune responses in BALB/c mice, with IgG antibody titers comparable to Complete Freund's Adjuvant (CFA). The vaccine induced Th1-skewed responses with IgG2a as the major antibody isotype, along with production of Th1 cytokines (IFN-?, IL-2) and Th2 cytokines (IL-4, IL-5). Induced antibodies showed high binding affinity to MUC1-expressing MCF-7 breast cancer cells and mediated strong complement-dependent cytotoxicity (CDC). The covalently conjugated vaccine demonstrated superior immunogenicity compared to non-covalent mixtures of antigen and adjuvant. The MUC1 glycopeptide epitope (TSAPDT(?-GalNAc)RPAP) was validated on both synthetic peptide and native MUC1 on MCF-7 cells. The Tn antigen (?-GalNAc) at threonine represents a tumor-associated carbohydrate antigen characteristic of aberrantly glycosylated MUC1 on cancer cells (Liu et al., 2017).
|
| Host Response |
|
|
| References |
Liu et al., 2017: Liu Z, Yang Y, Zhang X, Wang H, Xu W, Wang H, Xiao F, Bai Z, Yao H, Ma X, Jin L, Wu C, Seth P, Zhang Z, Wang L. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation. Human gene therapy. 2017; 28(8); 667-680. [PubMed: 28530155].
|
|
